HOME >> MEDICINE >> NEWS
Aspirin does not reduce effectiveness of ACE inhibitors

A systematic review in this week's issue of THE LANCET provides clarification for the debate about the use of angiotensin-converting-enzyme (ACE) inhibitors in combination with aspirin for the treatment of cardiovascular disease-combination therapy does not reduce the effect of ACE inhibition.

Previous research has suggested that ACE inhibitors may be less effective in patients who also receive aspirin for the treatment of cardiovascular disease. Salim Yusuf from McMaster University, Hamilton, Canada, and colleagues did a systematic overview of data from around 22,000 patients from six long-term randomised trials of ACE inhibitors to assess whether aspirin altered the effects of ACE inhibitor therapy on major clinical outcomes (a combination of death, heart attack, stroke, hospital admission for congestive heart failure, or coronary artery revascularisation).

With the exception of one randomised trial, the efficacy of ACE inhibitors was not found to be altered (either positively or negatively) among patients who were also receiving aspirin. Overall, ACE inhibitor therapy significantly reduced the risk of the major clinical outcomes by 22%, with clear reductions in the risk both among those receiving or not receiving aspirin at the start of the randomised trials.

Salim Yusuf comments: "Even though results from the present analyses cannot rule out the possibility of some sort of interaction, they show unequivocally that even if aspirin is given, the addition of ACE inhibitor therapy produced substantial additional benefit in all major vascular outcomes. Therefore, in the absence of clear contraindications, concomitant use of aspirin and ACE inhibitors should be considered in all patients at high risk of major vascular events."


'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-207-424-4949
Lancet
3-Oct-2002


Page: 1

Related medicine news :

1. Aspirins potential ability to prevent colon polyps may not apply equally to all
2. Aspirin underused to reduce heart disease risk in diabetic women and young adults
3. Long Island Breast Cancer Study data: Aspirin helps protect some women against breast cancer
4. Aspirin use associated with reduced risk of breast cancer
5. Aspirin use may be associated with increased risk of pancreatic cancer
6. Aspirin is most cost effective way to prevent heart disease
7. Aspirin withdrawal may pose risk to coronary patients
8. Aspirin may help prevent pancreatic cancer
9. Aspirins target, the COX-2 enzyme, linked to cancer of the uterus
10. Aspirin within two days of ischemic stroke reduces deaths
11. Aspirin steps up as anti-inflammatory for arteries

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... and clinical outcomes, hosted members and suppliers for its inaugural Member Conference at ... on their mission of elevating the operational health of America’s healthcare providers. , ...
(Date:5/26/2016)... ... ... Connor Sports, through its Connor Cares initiative, will continue to ... Legacy Tour that will commemorate the Indiana Fever legend’s hall-of-fame career and final ... and levels of the game, Connor Sports has committed to a significantly increased focus ...
(Date:5/26/2016)... Pompano Beach, Florida (PRWEB) , ... May 26, 2016 , ... ... Green House® Project offering a new model of care for living and ... on three core values: Meaningful Life in a Real Home provided by Empowered Staff. ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are nearly 14.5 ... 32 million cancer survivors worldwide. On Sunday, June 5, 2016, communities around the world ... Cancer Survivors Day®. , National Cancer Survivors Day® is an annual worldwide Celebration ...
(Date:5/26/2016)... ... 26, 2016 , ... Catalent Pharma Solutions, the leading global ... and global clinical supply services, today announced two key appointments and the opening ... and strategic growth plans in the Asia Pacific region. , Howard Kim has ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... -- MedDay, a biotechnology company focused on the ... entitled "High doses of biotin in progressive multiple sclerosis: extension ... Professor Ayman Tourbah , Principal Investigator of the Phase ... of Neurology (EAN) in Copenhagen, Denmark . ... place on Sunday, 29 May 2016 from 14:45 to 16:15 ...
(Date:5/24/2016)... 2016 Niederländische Chirurgen haben ... es Ärzten erlaubt, ihre Expertise weltweit zu teilen ... Live Streaming mit einer Instant-Messaging-Funktion und der Möglichkeit, ... in Europa, Afrika, Asien und den ... Plattform registriert. Information und Weiterbildung   ...
(Date:5/24/2016)...   , Study met both ... superiority in , Excellent plus Good ... of the ascending colon   , ... today announced new positive data from the phase III MORA study ... 2 litre PEG with ascorbate. The study met both primary endpoints ...
Breaking Medicine Technology:
Cached News: